Skip to main content
. 2023 Jun 26;93:104663. doi: 10.1016/j.ebiom.2023.104663

Fig. 8.

Fig. 8

HexaBody-CD38 induced potent CDC of primary MM cells ex vivo. CDC induction by HexaBody-CD38 and daratumumab in primary MM cells was determined ex vivo. Dose-dependent CDC by HexaBody-CD38 and daratumumab in a newly diagnosed MM patient sample (a) and a daratumumab-naïve RR patient sample (b). (c) CDC activity of 10 μg/mL HexaBody-CD38 and daratumumab in ND (n = 4), daratumumab-naïve RR (n = 3) and daratumumab-treated RR (n = 9) MM patient samples. The dotted line represents the background lysis (19%). Lines between HexaBody-CD38 and daratumumab symbols link values observed in the same samples. Open symbols represent CDC activity observed after incubation with 1 μg/mL instead of 10 μg/mL antibody.